- Home
- TVGN vs IPHA Comparison
TVGN vs IPHA Comparison
Compare TVGN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVGN
- IPHA
- Stock Information
- Founded
- TVGN 2020
- IPHA 1999
- Country
- TVGN United States
- IPHA France
- Employees
- TVGN N/A
- IPHA N/A
- Industry
- TVGN Blank Checks
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- TVGN Finance
- IPHA Health Care
- Exchange
- TVGN Nasdaq
- IPHA Nasdaq
- Market Cap
- TVGN 193.1M
- IPHA 160.1M
- IPO Year
- TVGN N/A
- IPHA 2019
- Fundamental
- Price
- TVGN $1.28
- IPHA $2.16
- Analyst Decision
- TVGN Strong Buy
- IPHA Strong Buy
- Analyst Count
- TVGN 1
- IPHA 1
- Target Price
- TVGN $10.00
- IPHA $11.00
- AVG Volume (30 Days)
- TVGN 675.8K
- IPHA 28.8K
- Earning Date
- TVGN 06-10-2025
- IPHA 03-27-2025
- Dividend Yield
- TVGN N/A
- IPHA N/A
- EPS Growth
- TVGN N/A
- IPHA N/A
- EPS
- TVGN N/A
- IPHA N/A
- Revenue
- TVGN N/A
- IPHA $20,831,349.00
- Revenue This Year
- TVGN N/A
- IPHA $209.83
- Revenue Next Year
- TVGN N/A
- IPHA $83.15
- P/E Ratio
- TVGN N/A
- IPHA N/A
- Revenue Growth
- TVGN N/A
- IPHA N/A
- 52 Week Low
- TVGN $0.26
- IPHA $1.29
- 52 Week High
- TVGN $3.09
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- TVGN 58.67
- IPHA 53.46
- Support Level
- TVGN $1.15
- IPHA $2.06
- Resistance Level
- TVGN $1.40
- IPHA $2.24
- Average True Range (ATR)
- TVGN 0.09
- IPHA 0.09
- MACD
- TVGN 0.01
- IPHA -0.01
- Stochastic Oscillator
- TVGN 56.25
- IPHA 53.33
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.